Skin Conditions & Dermatology Clinical Trials Update: Week 32, 2026

Published August 7, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

This Phase 3 study explored rocatinlimab combined with existing topical treatments for adults with moderate-to-severe atopic dermatitis. With 746 participants worldwide, the trial aimed to find a new way to reduce inflammation and improve the skin condition for people living with this long-term, often uncomfortable disease. Results are now available, potentially offering hope for better symptom control and skin healing.

Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine

This Phase 2 trial tested rilzabrutinib, an oral medication, in adults who continue to experience itching and hives from chronic spontaneous urticaria despite taking antihistamines. Including 160 participants, the study focused on finding a new treatment option for those whose symptoms are not well managed by current therapies. The results could lead to improved relief for patients struggling with persistent skin reactions.

Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents

This Phase 2b trial evaluated a bioengineered skin substitute designed for people with deep and full-thickness burns. Conducted with 14 participants across Europe, the study looked at an alternative to traditional skin grafts that could promote better healing and reduce complications. This approach may improve recovery outcomes and quality of life for burn patients.

Nonhealing Venous Leg Ulcers Treated With a Standard of Care (SoC) Alone or Standard of Care and Dehydrated Human Placenta Tissue (dHPT) With Crossover

This Phase 4 trial is testing whether adding dehydrated human placental tissue to usual wound care can help heal stubborn venous leg ulcers. Currently open to adults in the United States, this study could offer a new treatment that encourages faster or more complete healing compared to standard care alone. This might reduce discomfort and complications from chronic leg wounds.

Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata

This Phase 2 study is investigating VC005 tablets for people with severe alopecia areata, a condition that causes hair loss due to the immune system attacking hair follicles. Recruiting 120 participants in China, the trial aims to see if this new treatment can safely promote hair regrowth and improve patients’ quality of life. Results will help understand if VC005 could become a useful option for this challenging condition.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.